ETV4 promotes pancreatic ductal adenocarcinoma metastasis through activation of the CXCL13/CXCR5 signaling axis.

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  Qiong Lu,et al.  Function and regulation of the PEA3 subfamily of ETS transcription factors in cancer. , 2020, American journal of cancer research.

[3]  T. Starr,et al.  Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis. , 2020, Gastroenterology.

[4]  J. Valle,et al.  Pancreatic cancer , 2020, The Lancet.

[5]  A. Iuga,et al.  Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte–mediated immune suppression , 2020, Gut.

[6]  Bi-Jun Huang,et al.  ETV4 is a theranostic target in clear cell renal cell carcinoma that promotes metastasis by activating the pro-metastatic gene FOSL1 in a PI3K-AKT dependent manner. , 2020, Cancer letters.

[7]  E. Jaffee,et al.  Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. , 2020, The Lancet. Oncology.

[8]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[9]  Haitao Shen,et al.  ETV4 overexpression promotes progression of non–small cell lung cancer by upregulating PXN and MMP1 transcriptionally , 2019, Molecular carcinogenesis.

[10]  Y. Onodera,et al.  ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer , 2019, Proceedings of the National Academy of Sciences.

[11]  M. Kazanietz,et al.  CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond , 2019, Front. Endocrinol..

[12]  J. Soh,et al.  Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion. , 2019, Cancer letters.

[13]  D. Adah,et al.  CXCL13/CXCR5 signaling axis in cancer. , 2019, Life sciences.

[14]  J. Soh,et al.  Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness , 2019, Neoplasia.

[15]  Dingjun Zhu,et al.  CXCL13/CXCR5 Axis Predicts Poor Prognosis and Promotes Progression Through PI3K/AKT/mTOR Pathway in Clear Cell Renal Cell Carcinoma , 2019, Front. Oncol..

[16]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[17]  Heather E. Danysh,et al.  The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells , 2018, Neoplasia.

[18]  David Bonekamp,et al.  NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. , 2018, Cancer discovery.

[19]  S. Vacher,et al.  ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis , 2018, Breast Cancer Research.

[20]  M. Uguccioni,et al.  Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis , 2018, Arthritis Research & Therapy.

[21]  Sanguk Kim,et al.  Capicua suppresses hepatocellular carcinoma progression by controlling the ETV4–MMP1 axis , 2018, Hepatology.

[22]  Yun Wang,et al.  ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis. , 2018, Cancer research.

[23]  He Li,et al.  CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer , 2018, Cancer Immunology, Immunotherapy.

[24]  D. Kuprash,et al.  p63 and p73 repress CXCR5 chemokine receptor gene expression in p53-deficient MCF-7 breast cancer cells during genotoxic stress. , 2017, Biochimica et biophysica acta. Gene regulatory mechanisms.

[25]  Baowei Su,et al.  CXCR5+ CD8+ T cells potently infiltrate pancreatic tumors and present high functionality , 2017, Experimental cell research.

[26]  Aamir Ahmad,et al.  ETV4 Facilitates Cell-Cycle Progression in Pancreatic Cells through Transcriptional Regulation of Cyclin D1 , 2017, Molecular Cancer Research.

[27]  O. Wang,et al.  RSPO2 suppresses colorectal cancer metastasis by counteracting the Wnt5a/Fzd7-driven noncanonical Wnt pathway. , 2017, Cancer letters.

[28]  J. Blando,et al.  Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway. , 2017, Cell reports.

[29]  John G Doench,et al.  ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. , 2017, Cell reports.

[30]  B. Han,et al.  MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma , 2016, Oncotarget.

[31]  M. A. Afanasyeva,et al.  p53-dependent expression of CXCR5 chemokine receptor in MCF-7 breast cancer cells , 2015, Scientific Reports.

[32]  N. Eritja,et al.  ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas. , 2014, Carcinogenesis.

[33]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[34]  D. Zheng,et al.  ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.

[35]  M. Loda,et al.  ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. , 2013, Genes & development.

[36]  R. Janknecht,et al.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. , 2012, Biochimica et biophysica acta.

[37]  W. Ries,et al.  CXCL13 Activation of c-Myc Induce RANK Ligand Expression in Stromal/Preosteoblast Cells in the Oral Squamous Cell Carcinoma Tumor-Bone Microenvironment , 2012, Oncogene.

[38]  C. El-Haibi,et al.  CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation , 2011, Cell proliferation.

[39]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[40]  S. Rai,et al.  Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. , 2009, Cancer letters.

[41]  M. May,et al.  Constitutive noncanonical NFκB signaling in pancreatic cancer cells , 2009, Cancer biology & therapy.

[42]  M. Essafi,et al.  Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a , 2007, Oncogene.

[43]  M. Keating,et al.  Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. , 2007, Blood.

[44]  B. Sipos,et al.  The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. , 2006, Cancer research.

[45]  D. Bar-Sagi,et al.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.

[46]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[47]  Hiroyuki Yamamoto,et al.  Association of ets‐related transcriptional factor E1AF expression with tumour progression and overexpression of MMP‐1 and matrilysin in human colorectal cancer , 2003, The Journal of pathology.

[48]  A. Sharrocks.  The ETS-domain transcription factor family , 2001, Nature Reviews Molecular Cell Biology.

[49]  V. Sementchenko,et al.  Ets target genes: past, present and future , 2000, Oncogene.

[50]  M. Baggiolini,et al.  B Cell–attracting Chemokine 1, a Human CXC Chemokine Expressed in Lymphoid Tissues, Selectively Attracts B Lymphocytes via BLR1/CXCR5 , 1998, The Journal of experimental medicine.

[51]  T. Sawada,et al.  E‐selectin binding by pancreatic tumor cells is inhibited by cancer sera , 1994, International journal of cancer.